CN102048702B - A kind of bifendate nano crystal preparation and preparation method thereof - Google Patents
A kind of bifendate nano crystal preparation and preparation method thereof Download PDFInfo
- Publication number
- CN102048702B CN102048702B CN2010105720119A CN201010572011A CN102048702B CN 102048702 B CN102048702 B CN 102048702B CN 2010105720119 A CN2010105720119 A CN 2010105720119A CN 201010572011 A CN201010572011 A CN 201010572011A CN 102048702 B CN102048702 B CN 102048702B
- Authority
- CN
- China
- Prior art keywords
- suspension
- bifendate
- preparation
- nano
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 title claims abstract description 75
- 238000002360 preparation method Methods 0.000 title claims abstract description 75
- 239000002159 nanocrystal Substances 0.000 title claims description 23
- 239000000725 suspension Substances 0.000 claims abstract description 64
- 239000003381 stabilizer Substances 0.000 claims abstract description 23
- 239000003960 organic solvent Substances 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract 6
- 239000012154 double-distilled water Substances 0.000 claims abstract 5
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 120
- 235000010290 biphenyl Nutrition 0.000 claims description 62
- 239000004305 biphenyl Substances 0.000 claims description 62
- 238000007709 nanocrystallization Methods 0.000 claims description 62
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 23
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 15
- 229930195725 Mannitol Natural products 0.000 claims description 15
- 239000000594 mannitol Substances 0.000 claims description 15
- 235000010355 mannitol Nutrition 0.000 claims description 15
- 239000004094 surface-active agent Substances 0.000 claims description 13
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 11
- 235000010445 lecithin Nutrition 0.000 claims description 11
- 239000000787 lecithin Substances 0.000 claims description 11
- 229940067606 lecithin Drugs 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 9
- 238000000265 homogenisation Methods 0.000 claims description 9
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 9
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000000375 suspending agent Substances 0.000 claims description 6
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 5
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 5
- 229960000502 poloxamer Drugs 0.000 claims description 5
- 229920001983 poloxamer Polymers 0.000 claims description 5
- -1 polyoxyethylene Polymers 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- FDPIMTJIUBPUKL-UHFFFAOYSA-N dimethylacetone Natural products CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 claims description 4
- 239000002736 nonionic surfactant Substances 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- 229940069328 povidone Drugs 0.000 claims 2
- 229920002307 Dextran Polymers 0.000 claims 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 claims 1
- 229920000084 Gum arabic Polymers 0.000 claims 1
- 241000978776 Senegalia senegal Species 0.000 claims 1
- 239000000205 acacia gum Substances 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 abstract description 13
- 238000002347 injection Methods 0.000 abstract description 9
- 239000007924 injection Substances 0.000 abstract description 9
- 239000002775 capsule Substances 0.000 abstract description 2
- 239000002612 dispersion medium Substances 0.000 abstract 1
- 239000003223 protective agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 30
- 238000000034 method Methods 0.000 description 29
- 238000003756 stirring Methods 0.000 description 25
- 229940079593 drug Drugs 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 14
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 11
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 11
- 229910052782 aluminium Inorganic materials 0.000 description 11
- 238000007710 freezing Methods 0.000 description 11
- 230000008014 freezing Effects 0.000 description 11
- 238000004806 packaging method and process Methods 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 238000003860 storage Methods 0.000 description 11
- 238000005303 weighing Methods 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 229920002521 macromolecule Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000005484 Bifenox Substances 0.000 description 2
- SUSRORUBZHMPCO-UHFFFAOYSA-N MC-4379 Chemical compound C1=C([N+]([O-])=O)C(C(=O)OC)=CC(OC=2C(=CC(Cl)=CC=2)Cl)=C1 SUSRORUBZHMPCO-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 206010019759 Hepatitis chronic persistent Diseases 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- HTBWBWWADZJXID-TXEJJXNPSA-N Wuweizisu C Chemical compound COC1=C2C=3C(OC)=C4OCOC4=CC=3C[C@H](C)[C@H](C)CC2=CC2=C1OCO2 HTBWBWWADZJXID-TXEJJXNPSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- HTBWBWWADZJXID-UHFFFAOYSA-N gamma-schisandrin Natural products COC1=C2C=3C(OC)=C4OCOC4=CC=3CC(C)C(C)CC2=CC2=C1OCO2 HTBWBWWADZJXID-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000593 microemulsion method Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000006070 nanosuspension Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种联苯双酯纳米结晶制剂，包括原料和辅料，原料为联苯双酯，辅料为稳定剂，原料与辅料的重量份如下：联苯双酯200份，稳定剂20～400份。其制备方法为：(1)将稳定剂分散在双蒸水中以作为分散介质，得到混悬剂A；(2)将联苯双酯分散在有机溶剂中，得到粗混悬剂B；(3)将粗混悬剂B超声条件下分散于混悬剂A中，制得混悬剂C；(4)将混悬剂C通过高压微射流纳米分散仪均质，得联苯双酯纳米结晶混悬液；(5)将步骤(4)制得的联苯双酯纳米结晶混悬液冷冻干燥，或加入冻干保护剂后冷冻干燥，即得联苯双酯纳米结晶制剂。本发明的联苯双酯纳米结晶制剂在具体应用时，可以制成注射剂，也可以制成口服制剂，如片剂、胶囊剂等。
The invention discloses a bifendate nanocrystalline preparation, comprising raw materials and auxiliary materials, wherein the raw material is bifendate, and the auxiliary material is a stabilizer, and the weight proportions of the raw materials and the auxiliary materials are as follows: 200 parts of bifendate and 20 to 400 parts of the stabilizer. The preparation method thereof is as follows: (1) dispersing the stabilizer in double distilled water as a dispersion medium to obtain a suspension A; (2) dispersing the bifendate in an organic solvent to obtain a coarse suspension B; (3) dispersing the coarse suspension B in the suspension A under ultrasonic conditions to obtain a suspension C; (4) homogenizing the suspension C through a high-pressure microfluidizer nanodispersor to obtain a bifendate nanocrystalline suspension; (5) freeze-drying the bifendate nanocrystalline suspension obtained in step (4), or freeze-drying after adding a freeze-drying protective agent, to obtain the bifendate nanocrystalline preparation. The bifendate nanocrystalline preparation of the invention can be prepared into an injection or an oral preparation, such as a tablet, a capsule, etc., when used in a specific application.
Description
Technical field
The present invention relates to a kind of biphenyl dimethylesterate nano crystallization preparation and preparation method thereof
Background technology
Bifendate (Bifendate): being the intermediate of synthetic schisandrin C, is the hepatoprotective of efficient, the low toxicity with new structure of China initiative.Its chemistry is called 4,4 '-dimethoxy-5,6, and 5 ', 6 '-secondary first dioxy-2,2 '-dioctyl phthalate methyl ester biphenyl, molecular formula is: C
20H
18O
10, molecular weight is: 419.36.These article are a kind of white crystalline powder, and odorless, tasteless is water-soluble hardly, is slightly soluble in methanol and ethanol, are soluble in chloroform, dimethyl formamide season pyridine, are certain fat-soluble.
Clinical research shows that the main pharmacological of bifendate has: (1) has significant function for protecting liver and reducing enzyme activity: can obviously reduce serum glutamic pyruvic transminase (glutamic pyrumic transaminase; GPT) and glutamic oxaloacetic transaminase, GOT (glutamic Oxalictransaminase, GOT); (2) strengthen the function of detoxification of liver: the content of hepatomicrosome such as P-450 is significantly increased, and then strengthen the detoxification ability of liver; (3) the liver protecting is avoided the poisonous substance damage: alleviate the hepatic injury that is caused by chemical substances such as carbon tetrachloride, anticarcinogen, antitubercular agents; The effect of (4) anti-cell sudden change, necrosis.This poison of drug property is very low, and no teratogenesis tire, mutagenic action are a kind of relatively safe drugs, and cheap, easy for patients to accept, thereby have good research and application prospect.At present this medicine is clinical is used for the gpt activity rising person that chronic persistent hepatitis is followed, and also can be used for chemical toxicant, drug-induced gpt activity raises.
The almost water-fast character of bifendate makes the external stripping of its preparation poor, though in gastrointestinal tract, be not destroyed, the serious liver first-pass effect in oral back causes this medicine oral administration biaavailability low, generally has only 25%～30%.Bifendate get in the body back at liver rapidly by metabolic conversion, plasma half-life had only about 5 hours, 70% discharges from feces after 24 hours.Though only absorb about 25%, show the very strong GPT effect of falling, explain that its biological activity is very high, be one the researching value medicine to be arranged.The preparation that uses at present or study mainly contains Bifendate Tablet, Bifendate, bifendate drop pill, compound bifenox sheet, compound bifenox electuary, bifendate oral administration mixed suspension etc.; CN 200410070669.4 discloses a kind of bifendate oral disintegration tablet, CN 03145971.4 discloses a kind of bifendate slow releasing preparation; Because bifendate is water insoluble, so the low shortcoming of these preparation ubiquity bioavailability.CN 03146030.5 discloses a kind of biphenyl diester emulsion, CN 100998561A discloses a kind of bifendate intravenous injection emulsion, and liquid preparation stores and the transportation inconvenience, also causes medicine unstable easily.CN 200610038662.3 discloses a kind of bifendate solid dispersion, CN 200810234507.8 discloses a kind of self-emulsifying formulation of biphenyldicarboxylatand to improve its bioavailability and stability.
Bifendate is as a kind of medicine of life-time service, and a kind of administration number of times of clinical needs is few, bioavailability is high, good stability, preparation simply help the preparation that the patient uses.
Nanocrystal (nanocrystals): in recent years by stable the increasing of quantity of the activity chemistry entity of screening such as combinatorial chemistry preparation, but major part is a hydrophobic compound.According to statistics, have 40% to be insoluble in water in the medicine that obtains through high flux screening at present, and this situation reach 60% in the medicine that obtains through direct synthesis technique.Insoluble drug usually is difficult to reach the bioavailability that the treatment disease requires after oral through traditional formulation method, or is difficult to process the preparation that supplies intravenously administrable, thus big limitations the application of medicine.The preparation work person has taked a lot of methods to solve this problem, as using mixed solvent, adopt inclusion technique, micronization or processing vein emulsion etc.Avoid the drawback of said method up to 1994 by the nanocrystal of reported first such as M ü ller, had clear superiority.
Nanocrystal is to utilize the Stabilization of surfactant, and drug particles is dispersed in the water, forms the stabilized nano colloidal dispersion through pulverizing or control the crystallize technology.The charge effect that the pure drug particles of nanoscale particle diameter relies on surfactant in the system is or/and stereoeffect stably is suspended in the solution, and the mean diameter of its Chinese medicine is less than 1 μ m, generally between 100～500nm.Nanocrystal can further be prepared as the pharmaceutical dosage form that is fit to oral, injection or other administration route, thereby improves the absorption and the bioavailability of medicine.And nanocrystal can improve the drug loading in the preparation, is particularly suitable for the oral and drug administration by injection of heavy dose, insoluble drug.In addition, owing to do not contain carrier and cosolvent in the prescription, the toxic and side effects of drug administration by injection is lower.
Deposition-high pressure homogenization method (high-pressure homogenization): the method for preparing of nanocrystal mainly contains grinding method, high pressure homogenization method, the sedimentation method, deposition-high pressure homogenization method, emulsion process and microemulsion method etc.
In sum, bifendate is processed nano crystallization preparation, expection can reach that toxic and side effects is little, system is stable, can increase purpose such as bioavailability of medicament.Do not see in the prior art relevant for the report of bifendate being processed nano crystallization preparation.Lack in the prior art under the situation of relevant report; Develop and a kind ofly have that good effect, good biocompatibility, bioavailability are high, system stablizes, is applicable to that the biphenyl dimethylesterate nano crystallization preparation of large-scale industrial production, low cost and other advantages and method for preparing are difficult points; Creative work need be paid, lot of test and conditional filtering need be carried out.
Summary of the invention
To above-mentioned prior art; Clinical practice limitation to the bifendate poorly water-soluble; The invention provides a kind of new architecture of bifendate: biphenyl dimethylesterate nano crystallization preparation, calcium preparation can increase the bioavailability of bifendate, and toxic and side effects is little, system stable.The present invention also provides the method for preparing of this biphenyl dimethylesterate nano crystallization preparation, and this method can adopt conventional process equipment, is fit to the extensive high benefit production of industry.
The present invention realizes through following technical scheme:
A kind of biphenyl dimethylesterate nano crystallization preparation comprises raw material and adjuvant, and raw material is a bifendate, and adjuvant is a stabilizing agent, and the weight portion of raw material and adjuvant is following: 200 parts of bifendate, 20～400 parts of stabilizing agents; Wherein, Said stabilizing agent comprises surfactant and the agent of macromolecule suspending; Surfactant is selected from one or more in fatty glyceride, polyol-based non-ionic surfactant, polyoxyethylene-type non-ionic surface active agent, poloxamer, the lecithin; The agent of macromolecule suspending is selected from one or more in arabic gum, hydroxypropyl cellulose, methylcellulose, polyvidone, carbopol, the glucosan, and the consumption mass ratio of surfactant and the agent of macromolecule suspending is 1: 4.
The weight portion of said raw material and adjuvant is preferably following: 200 parts of bifendate, 20～400 parts of stabilizing agents; Further preferred, for: 200 parts of bifendate, 20～300 parts of stabilizing agents.
A kind of method for preparing of biphenyl dimethylesterate nano crystallization preparation may further comprise the steps:
(1) stabilizing agent is dispersed in the distilled water with as disperse medium, obtains suspensoid A;
(2) bifendate is dispersed in the organic solvent, obtains thick suspensoid B;
(3) be scattered under the thick suspensoid B ultrasonic sound condition that step (2) is made among the water disperse medium suspensoid A that step (1) makes, make suspensoid C;
(4) the suspensoid C that step (3) is made is through high pressure microjet nano-dispersed appearance homogenizing 1～20 time under the pressure of 4660psig～27960psig, biphenyl dimethylesterate nano crystallization suspension;
(5) the biphenyl dimethylesterate nano crystallization suspension lyophilization that step (4) is made, or add the freeze drying protectant postlyophilization, promptly get biphenyl dimethylesterate nano crystallization preparation.
In the said step (1), when stabilizing agent was dispersed in the distilled water, the two following with magnitude relation: per 0.2～20g stabilizing agent was dispersed in the 100ml water.
In the said step (2); When bifendate is dispersed in the organic solvent; The two following with magnitude relation: per 0.2～20g bifendate is dispersed in the step described in 1～10ml organic solvent (2), and organic solvent is selected from one or more in chloroform, acetone, ethanol, ethyl acetate, isopropyl alcohol, PEG400, the dimethyl sulfoxide.
In the said step (4), the concrete operations of homogenizing are: homogenizing 2 times respectively under the pressure of 6990psig and 11650psig, homogenizing 10 times under 23300psig pressure then.
In the said step (5), freeze drying protectant is selected from one or more in mannitol, sucrose, lactose, galactose, chitosan, the trehalose.
In the said step (5), the addition of freeze drying protectant is 1%～10% (w/v) of biphenyl dimethylesterate nano crystallization suspension, unit: g:ml.
Preferably, said method for preparing concrete steps are following:
(1) with the surfactant-dispersed of the macromolecule suspending agent of 0.05g and 0.2g in the 100ml distilled water with as disperse medium, obtain suspensoid A; Wherein, the agent of macromolecule suspending is polyvidone or hydroxypropyl cellulose, and surfactant is a lecithin;
(2) the 0.2g bifendate is dispersed in the 5ml organic solvent, obtains thick suspensoid B; Wherein, organic solvent is that dimethyl sulfoxide, acetone or volume ratio are acetone-PEG400 mixture of 1: 1;
(3) be scattered under the thick suspensoid B ultrasonic sound condition that step (2) is made among the water disperse medium suspensoid A that step (1) makes, make suspensoid C;
(4) the suspensoid C that step (3) is made distinguishes homogenizing 2 times through high pressure microjet nano-dispersed appearance under the pressure of 6990psig and 11650psig, homogenizing 10 times under 23300psig pressure then must biphenyl dimethylesterate nano crystallization suspension;
(5) in the biphenyl dimethylesterate nano crystallization suspendible liquid cooling that step (4) makes, add freeze drying protectant mannitol, addition is 5% of a biphenyl dimethylesterate nano crystallization suspension, unit: g:ml, and lyophilization promptly gets biphenyl dimethylesterate nano crystallization preparation.The method for preparing of biphenyl dimethylesterate nano crystallization preparation of the present invention; Adopt deposition-high pressure homogenization method; It is earlier medicine to be dissolved in the organic solvent; Join in the aqueous solution that contains surfactant at the organic solvent that is dissolved with medicine following of low temperature condition of stirring then, under the effect of high pressure microjet nano-dispersed appearance, make nanocrystal behind the ultrasonic reasonable time of low temperature.This law has combined the advantage of the sedimentation method and high pressure homogenization method, also is suitable for preparing the aseptic nanocrystal of injection.
The prepared biphenyl dimethylesterate nano crystallization preparation that obtains of the present invention can be processed injection and use when concrete the application, and toxic and side effects is little, and system is stable; Also can process oral formulations, like tablet, capsule etc.
The present invention to increase its curative effect and to expand clinical practice, has adopted suitable stabilizing agent and high pressure homogenization method to prepare the biphenyl dimethylesterate nano crystallization in order to improve bifendate oral administration biaavailability and preparation injection bifendate.Stabilizing agent used in the present invention and freeze drying protectant are the adjuvant of field of pharmaceutical preparations extensive use, no immunostimulating, and no physiology toxicity, non-responsiveness property has excellent biological compatibility.The present invention selects suitable homogenization pressure and stabilizer concentration and composition through process optimization and prescription screening, can prepare that size can be controlled, stability biphenyl dimethylesterate nano crystallization preferably.The biphenyl dimethylesterate nano crystallization suspension that method of the present invention prepares is observed under transmission electron microscope; It is thus clear that bifendate is spherical entity particle; Surfaces coated is covered with stabilizing agent; Kernel is the bifendate crude drug, and particle diameter can judge that according to the form and the size of particle said preparation is the biphenyl dimethylesterate nano crystallization between 20～1000nm.In addition, biphenyl dimethylesterate nano crystallization suspension is mixed the biphenyl dimethylesterate nano crystallization that makes after the lyophilization again with freeze drying protectant; With carrying out grain diameter measurement again after its redissolution; Particle diameter also can confirm the formation of nano crystallization preparation at 100～1000nm, and is as shown in Figure 1.
The present invention has overcome the defective that bifendate is insoluble in water; The prepared nanocrystal of the present invention can significantly improve the dissolution in vitro degree and the dissolution rate of bifendate; Carry out for being released under the sink condition of medicine of assurance, this paper studies the release behaviour in vitro of DDB-NSP dried frozen aquatic products and crude drug powder with the stirring arm method, and the dissolution data of gained DDB crude drug and DDB-NSP freeze-dried powder is made accumulative total stripping quantity-time graph; Can obviously see with bifendate process nanocrystalline after; Compare with crude drug and obviously to have improved it and dissolve in speed, see Fig. 3 (p＜0.05), like embodiment 1.
The preparation technology of biphenyl dimethylesterate nano crystallization preparation of the present invention is easy to amplify; Prescription is simple, with improving stability of drug after its lyophilization, reduces the administration volume; Making oral administration nanometer crystallization suspensoid helps the swallow crowd of difficulty such as child and old man and is suitable for; Increase bioavailability, reduce dosage, reduce toxic and side effects; Make the pain that the injection lyophilized powder helps reducing the toxicity that increases other complicated adjuvant and extreme pH, help being suitable for of emergency case patient with severe symptoms.
Description of drawings
Fig. 1: the transmission electron microscope photo of the nanocrystal that bifendate and stabilizing agent form.
Fig. 2: be the particle size distribution figure (title: particle size distribution (Size distribution (s)), abscissa: particle diameter (Diameter), vertical coordinate: percentage rate (%in class) of biphenyl dimethylesterate nano suspension.
The external stripping curve (n=3) of Fig. 3: DDB-NSP and crude drug.
The specific embodiment
Below in conjunction with embodiment the present invention is done detailed elaboration, but protection scope of the present invention is not limited to the embodiment of these concrete records.
Embodiment 1: preparation biphenyl dimethylesterate nano crystallization preparation
Taking by weighing the 0.2g bifendate is dissolved in the 5ml dimethyl sulfoxide;, low temperature injects the aqueous solution that 100ml contains 0.05g polyvidone (k30), 0.2g lecithin under stirring; Behind the ultrasonic 40min of low temperature; Again through high pressure microjet nano-dispersed appearance with the pressure of 6990psig, 11650psig homogenizing 2 times respectively, homogenizing 10 times under 23300psig pressure promptly gets biphenyl dimethylesterate nano crystallization suspension then.
Get above-mentioned suspension according to 5% (w/v, g/ml) ratio adds mannitol, is filled to cillin bottle according to 2mL/ bottle branch after the stirring and dissolving; Put into ultra cold storage freezer rapidly; Under-80 ℃ of temperature freezing 24 hours, take out again and put into temperature rapidly and reduce on-50 ℃ the freeze dryer shelf, cover vacuum (-tight) housing; The open vacuum switch pump, lyophilizing 48 hours.Lyophilizing finishes the back and takes out back pressurization aluminum cap packaging, promptly gets the biphenyl dimethylesterate nano crystallization.Adopt the stirring paddle method to carry out external dissolution test lyophilized powder and crude drug, the result sees Fig. 3, can obviously see with bifendate process nanocrystalline after, compare it with crude drug and dissolve in speed and obviously improved.
Get above-mentioned DDB-NSP freeze-dried powder redissolution back liquid and be diluted to certain multiple, transmission electron microscope is observed down, and is as shown in Figure 1; Particle size distribution figure is as shown in Figure 2, and particle diameter is in 60～340nm scope.
Embodiment 2: preparation biphenyl dimethylesterate nano crystallization preparation
Taking by weighing the 2.5g bifendate is dissolved in the 5ml dimethyl sulfoxide; Stirring down at low temperature, injection 100ml contains 5g polyvidone k30), the aqueous solution of 1g lecithin; Behind the ultrasonic 40min of low temperature; Again through high pressure microjet nano-dispersed appearance with the pressure of 6990psig, 11650psig homogenizing 2 times respectively, homogenizing 10 times under 23300psig pressure promptly gets biphenyl dimethylesterate nano crystallization suspension then.
Get above-mentioned suspension according to 5% (w/v, g/ml) ratio adds mannitol, is filled to cillin bottle according to 2mL/ bottle branch after the stirring and dissolving; Put into ultra cold storage freezer rapidly; Under-80 ℃ of temperature freezing 24 hours, take out again and put into temperature rapidly and reduce on-50 ℃ the freeze dryer shelf, cover vacuum (-tight) housing; The open vacuum switch pump, lyophilizing 48 hours.Lyophilizing finishes the back and takes out back pressurization aluminum cap packaging, promptly gets the biphenyl dimethylesterate nano crystallization.
Embodiment 3: preparation biphenyl dimethylesterate nano crystallization preparation
Taking by weighing the 5g bifendate is dissolved in the 5ml dimethyl sulfoxide;, low temperature injects the aqueous solution that 100ml contains 2.5g hydroxypropyl cellulose, 2g lecithin under stirring; Behind the ultrasonic 40min of low temperature; With the pressure of 6990psig, 11650psig homogenizing 2 times respectively, homogenizing 10 times under 23300psig pressure promptly gets biphenyl dimethylesterate nano crystallization suspension then.
Get above-mentioned suspension and add mannitol according to 5% (w/v) ratio; Be filled to cillin bottle according to 2mL/ bottle branch after the stirring and dissolving, put into ultra cold storage freezer rapidly, under-80 ℃ of temperature freezing 24 hours; Take out again and put into temperature rapidly and reduce on-50 ℃ the freeze dryer shelf; Cover vacuum (-tight) housing, open vacuum switch pump, lyophilizing 48 hours.Lyophilizing finishes the back and takes out back pressurization aluminum cap packaging, promptly gets the biphenyl dimethylesterate nano crystallization.
Embodiment 4: preparation biphenyl dimethylesterate nano crystallization preparation
Taking by weighing the 2g bifendate is dissolved in the 10ml dimethyl sulfoxide;, low temperature injects the aqueous solution that 100ml contains 1g hydroxypropyl cellulose, 2g poloxamer under stirring; Behind the ultrasonic 40min of low temperature; With the pressure of 6990psig, 11650psig homogenizing 2 times respectively, homogenizing 10 times under 23300psig pressure promptly gets biphenyl dimethylesterate nano crystallization suspension then.
Get above-mentioned suspension and add mannitol according to 5% (w/v) ratio; Be filled to cillin bottle according to 2mL/ bottle branch after the stirring and dissolving, put into ultra cold storage freezer rapidly, under-80 ℃ of temperature freezing 24 hours; Take out again and put into temperature rapidly and reduce on-50 ℃ the freeze dryer shelf; Cover vacuum (-tight) housing, open vacuum switch pump, lyophilizing 48 hours.Lyophilizing finishes the back and takes out back pressurization aluminum cap packaging, promptly gets the biphenyl dimethylesterate nano crystallization.
Embodiment 5: preparation biphenyl dimethylesterate nano crystallization preparation
Taking by weighing the 0.2g bifendate is dissolved in the 1ml dimethyl sulfoxide;, low temperature injects the aqueous solution that 100ml contains 2g hydroxypropyl cellulose, 2g poloxamer under stirring; Behind the ultrasonic 40min of low temperature; With the pressure of 6990psig, 11650psig homogenizing 2 times respectively, homogenizing 10 times under 23300psig pressure promptly gets biphenyl dimethylesterate nano crystallization suspension then.
Get above-mentioned suspension and add mannitol according to 5% (w/v) ratio; Be filled to cillin bottle according to 2mL/ bottle branch after the stirring and dissolving, put into ultra cold storage freezer rapidly, under-80 ℃ of temperature freezing 24 hours; Take out again and put into temperature rapidly and reduce on-50 ℃ the freeze dryer shelf; Cover vacuum (-tight) housing, open vacuum switch pump, lyophilizing 48 hours.Lyophilizing finishes the back and takes out back pressurization aluminum cap packaging, promptly gets the biphenyl dimethylesterate nano crystallization.
Embodiment 6: preparation biphenyl dimethylesterate nano crystallization preparation
Taking by weighing the 2.5g bifendate is dissolved in the 6ml dimethyl sulfoxide;, low temperature injects the aqueous solution that 100ml contains 3g hydroxypropyl cellulose, 2g poloxamer under stirring; Behind the ultrasonic 40min of low temperature; With the pressure of 6990psig, 11650psig homogenizing 2 times respectively, homogenizing 10 times under 23300psig pressure promptly gets biphenyl dimethylesterate nano crystallization suspension then.
Get above-mentioned suspension and add mannitol according to 5% (w/v) ratio; Be filled to cillin bottle according to 2mL/ bottle branch after the stirring and dissolving, put into ultra cold storage freezer rapidly, under-80 ℃ of temperature freezing 24 hours; Take out again and put into temperature rapidly and reduce on-50 ℃ the freeze dryer shelf; Cover vacuum (-tight) housing, open vacuum switch pump, lyophilizing 48 hours.Lyophilizing finishes the back and takes out back pressurization aluminum cap packaging, promptly gets the biphenyl dimethylesterate nano crystallization.
Embodiment 7: preparation biphenyl dimethylesterate nano crystallization preparation
Taking by weighing the 5g bifendate is dissolved in the 10ml dimethyl sulfoxide;, low temperature injects the aqueous solution that 100ml contains 2.5g polyvidone (k30), 5g lecithin under stirring; Behind the ultrasonic 40min of low temperature; Again through high pressure microjet nano-dispersed appearance with the pressure of 6990psig, 11650psig homogenizing 2 times respectively, homogenizing 10 times under 23300psig pressure promptly gets biphenyl dimethylesterate nano crystallization suspension then.
Get above-mentioned suspension according to 5% (w/v, g/ml) ratio adds mannitol, is filled to cillin bottle according to 2mL/ bottle branch after the stirring and dissolving; Put into ultra cold storage freezer rapidly; Under-80 ℃ of temperature freezing 24 hours, take out again and put into temperature rapidly and reduce on-50 ℃ the freeze dryer shelf, cover vacuum (-tight) housing; The open vacuum switch pump, lyophilizing 48 hours.Lyophilizing finishes the back and takes out back pressurization aluminum cap packaging, promptly gets the biphenyl dimethylesterate nano crystallization.
Embodiment 8: preparation biphenyl dimethylesterate nano crystallization preparation
Taking by weighing the 0.2g bifendate is dissolved in the 5ml dimethyl sulfoxide; Under low temperature stirs, inject 100ml and contain 0.25 polyvidone (k30), 0.5g polyoxyethylene castor oil aqueous solution; Behind the ultrasonic 40min of low temperature; With the pressure of 6990psig, 11650psig homogenizing 2 times respectively, homogenizing 10 times under 23300psig pressure promptly gets biphenyl dimethylesterate nano crystallization suspension then.
Get above-mentioned suspension and add mannitol according to 5% (w/v) ratio; Be filled to cillin bottle according to 2mL/ bottle branch after the stirring and dissolving, put into ultra cold storage freezer rapidly, under-80 ℃ of temperature freezing 24 hours; Take out again and put into temperature rapidly and reduce on-50 ℃ the freeze dryer shelf; Cover vacuum (-tight) housing, open vacuum switch pump, lyophilizing 48 hours.Lyophilizing finishes the back and takes out back pressurization aluminum cap packaging, promptly gets the biphenyl dimethylesterate nano crystallization.
Embodiment 9: preparation biphenyl dimethylesterate nano crystallization preparation
Taking by weighing the 0.2g bifendate is dissolved in the 5ml acetone;, low temperature injects the aqueous solution aqueous solution that 100ml contains 0.05g polyvidone (k30), 0.2g lecithin under stirring; Behind the ultrasonic 40min of low temperature; With the pressure of 6990psig, 11650psig homogenizing 2 times respectively, homogenizing 10 times under 23300psig pressure promptly gets biphenyl dimethylesterate nano crystallization suspension then.
Get above-mentioned suspension and add mannitol according to 5% (w/v) ratio; Be filled to cillin bottle according to 2mL/ bottle branch after the stirring and dissolving, put into ultra cold storage freezer rapidly, under-80 ℃ of temperature freezing 24 hours; Take out again and put into temperature rapidly and reduce on-50 ℃ the freeze dryer shelf; Cover vacuum (-tight) housing, open vacuum switch pump, lyophilizing 48 hours.Lyophilizing finishes the back and takes out back pressurization aluminum cap packaging, promptly gets the biphenyl dimethylesterate nano crystallization.
Embodiment 10: preparation biphenyl dimethylesterate nano crystallization preparation
Taking by weighing the 0.2g bifendate is dissolved among 5ml acetone-PEG400 (1: 1);, low temperature injects the aqueous solution aqueous solution that 100ml contains 0.05g polyvidone (k30), 0.2g lecithin under stirring; Behind the ultrasonic 40min of low temperature; With the pressure of 6990psig, 11650psig homogenizing 2 times respectively, homogenizing 10 times under 23300psig pressure promptly gets biphenyl dimethylesterate nano crystallization suspension then.
Get above-mentioned suspension and add mannitol according to 5% (w/v) ratio; Be filled to cillin bottle according to 2mL/ bottle branch after the stirring and dissolving, put into ultra cold storage freezer rapidly, under-80 ℃ of temperature freezing 24 hours; Take out again and put into temperature rapidly and reduce on-50 ℃ the freeze dryer shelf; Cover vacuum (-tight) housing, open vacuum switch pump, lyophilizing 48 hours.Lyophilizing finishes the back and takes out back pressurization aluminum cap packaging, promptly gets the biphenyl dimethylesterate nano crystallization.
Embodiment 11: preparation biphenyl dimethylesterate nano crystallization preparation
Taking by weighing the 0.2g bifendate is dissolved in the 5ml acetone;, low temperature injects the aqueous solution that 100ml contains 0.05g hydroxypropyl cellulose, 0.20g lecithin under stirring; Behind the ultrasonic 40min of low temperature; With the pressure of 6990psig, 11650psig homogenizing 2 times respectively, homogenizing 10 times under 23300psig pressure promptly gets biphenyl dimethylesterate nano crystallization suspension then.
Get above-mentioned suspension and add mannitol according to 5% (w/v) ratio; Be filled to cillin bottle according to 2mL/ bottle branch after the stirring and dissolving, put into ultra cold storage freezer rapidly, under-80 ℃ of temperature freezing 24 hours; Take out again and put into temperature rapidly and reduce on-50 ℃ the freeze dryer shelf; Cover vacuum (-tight) housing, open vacuum switch pump, lyophilizing 48 hours.Lyophilizing finishes the back and takes out back pressurization aluminum cap packaging, promptly gets the biphenyl dimethylesterate nano crystallization.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105720119A CN102048702B (en) | 2010-12-03 | 2010-12-03 | A kind of bifendate nano crystal preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105720119A CN102048702B (en) | 2010-12-03 | 2010-12-03 | A kind of bifendate nano crystal preparation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102048702A CN102048702A (en) | 2011-05-11 |
| CN102048702B true CN102048702B (en) | 2012-05-23 |
Family
ID=43953726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105720119A Expired - Fee Related CN102048702B (en) | 2010-12-03 | 2010-12-03 | A kind of bifendate nano crystal preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102048702B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102846554B (en) * | 2012-09-28 | 2014-11-26 | 山东大学 | H2 nanocrystal preparation and preparation method thereof |
| CN102895185B (en) * | 2012-11-05 | 2015-03-25 | 西安德天药业股份有限公司 | Bifendate rapid-release pellet and preparation method and application thereof |
| CN105796492B (en) * | 2016-04-07 | 2019-07-02 | 中山大学 | Rivaroxaban nanosuspension and preparation method thereof |
| CN113069433B (en) * | 2021-04-16 | 2022-08-02 | 北京中医药大学 | Euphorbia lathyris element nanometer preparation and preparation method and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060003012A9 (en) * | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
| MXPA04002446A (en) * | 2001-09-26 | 2004-07-23 | Baxter Int | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal. |
| GB0216700D0 (en) * | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
| KR20100052262A (en) * | 2008-11-10 | 2010-05-19 | (주)아모레퍼시픽 | Process for preparing powder comprising nanoparticles of sparingly soluble drug, powder prepared by same process and pharmaceutical composition comprising same powder |
-
2010
- 2010-12-03 CN CN2010105720119A patent/CN102048702B/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| Lei Gao 等.Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system.《Journal of Nanoparticle Research》.2008,第10卷(第5期),845-862. * |
| Lei Gao 等.Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement.《Drug Development and Industrial Pharmacy》.2007,第33卷(第12期),1332-1339. * |
| 张熹 等.纳米结晶在难溶性药物口服给药中的应用.《中国医药工业杂志》.2009,第40卷(第11期),1-10. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102048702A (en) | 2011-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jacob et al. | Emerging role of nanosuspensions in drug delivery systems | |
| ES2334991T3 (en) | FARMACO MICROPARTICLES. | |
| Xiong et al. | Preparation and characterization of intravenously injectable nimodipine nanosuspension | |
| Kalia et al. | Solid dispersions: an approach towards enhancing dissolution rate | |
| CN103211759B (en) | Puerarin nanocrystalline medical composition and preparation method thereof | |
| CA2371912A1 (en) | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof | |
| CN104398477B (en) | A kind of usnic acid nanosuspension and its production and use | |
| JP2001509518A (en) | Nanocrystalline preparation of human immunodeficiency virus (HIV) protease inhibitor using cellulosic surface stabilizer and method for producing such preparation | |
| JP2010241820A (en) | Redispersible nanoparticulate film matrix with protective overcoat | |
| CN102824356A (en) | Baicalin nano crystal suspension, nano crystal dry powder and methods for preparing baicalin nano crystal suspension and nano crystal dry powder | |
| CN102370622A (en) | Medicament carrying nano particles and preparation method and application thereof | |
| CN102048702B (en) | A kind of bifendate nano crystal preparation and preparation method thereof | |
| EP1658052B1 (en) | Particle size reduction of bioactive compounds | |
| CN102488673A (en) | Probucol nanometer dispersion and preparation method thereof | |
| CN101961320A (en) | Budesonide nano crystallizing preparation and preparation method thereof | |
| Vadlamudi et al. | Disparate practical way of doing solubility enhancement study to improve the bioavailability of poorly soluble drugs | |
| CN103228266B (en) | Ternary mixture preparation | |
| Han et al. | In vitro and in vivo evaluation of core–shell mesoporous silica as a promising water-insoluble drug delivery system: Improving the dissolution rate and bioavailability of celecoxib with needle-like crystallinity | |
| JP2018508487A (en) | Dutasteride-containing solid dispersion and composition containing the same | |
| CN102133177B (en) | Plagiochin nanocrystal preparation and preparation method thereof | |
| CN102579373B (en) | Amoitone B nano crystallization preparation and preparation method thereof | |
| CN103263385B (en) | A kind of celecoxib long-acing nano injection and preparation method thereof | |
| Soujanya et al. | A Review on Novel Vesicular Drug Delivery System: Proniosomes. | |
| CN102846554B (en) | H2 nanocrystal preparation and preparation method thereof | |
| CN102631326A (en) | Sustained release microsphere used for injection and preparation method and applications of sustained release microsphere |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120523 Termination date: 20121203 |